EL7.AI
StocksMediumUpdated•Originally published 5 November 2026•Updated 5 November 2026•
1 min read

Halozyme Raises FY2026 Guidance Following Record Q3 Royalty Revenue

Key Facts

1Halozyme achieved record ENHANZE royalty revenue of $341 million in the third quarter.
2The company raised its full-year non-GAAP EPS guidance to a range of $8.75-$9.05.
3Revenue climbed 39.1% year over year with third-quarter non-GAAP EPS reaching $2.39.

Halozyme raised its full-year 2026 non-GAAP EPS guidance to a range of $8.75 to $9.05. 24/7 Wall St. reported that the company achieved record ENHANZE technology royalty revenue of $341 million in the third quarter, driving a 39.1% year-over-year increase in total revenue. Non-GAAP EPS for the quarter reached $2.39, supported by strong commercial performance from partner products.

Royalty revenue surged 44% compared to the previous year, fueled by the market success of partnered drugs including DARZALEX SC and VYVGART Hytrulo. According to 24/7 Wall St., the company also secured a legal victory in a Dutch court protecting its patents against Merck, which blocks the launch of competing products in multiple European markets. Despite the guidance hike and record financials, Halozyme shares saw a slight decline in the minutes following the release on November 5, 2026.

Latest Updates · 1

  1. Notable·

    Update: Halozyme's total Q3 revenue reached $493 million, surpassing analyst estimates of $486.4 million. Non-GAAP EPS also beat expectations by 1.5%, further reinforcing the strong financial performance reported by the company on November 5, 2026.

Open on chart